SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support healthcare professionals in identifying acute inpatient deterioration using AI-enabled machine learning models. Compared to the current standard of care, 1Bio™AI-Acute delivers significantly higher precision in acute deterioration notifications, resulting in fewer false alerts and more efficient clinical support.
The 1Bio™AI-Acute system uses only bedside-recorded vital signs—pulse rate, respiratory rate, oxygen saturation, and systolic blood pressure—to generate a probability score that assists clinicians in determining whether additional monitoring may be required. This score provides an indication of the patient's general physiological state: the higher the score, the greater the likelihood that the patient may require additional monitoring due to potential acute deterioration.
WHY IT MATTERS
"Current early-warning scores that rely on threshold-based methods often suffer from low precision, leading to a high number of alarms and notifications. Advanced AI-driven machine learning models have the potential to deliver significantly greater precision, reducing unnecessary alerts/notifications, thus enabling healthcare professionals to better focus their time on delivering quality patient care," said Dr. Gurpreet Singh, CEO and Founder of Respiree.
The 1Bio™AI-Acute is readily available to healthcare professionals through Respiree's 1Bio™ platform, which recently received regulatory clearance together with the RS001 wearable device. With this milestone, the 1Bio™AI-Acute toolbox, the 1Bio™platform, and the RS001 wearable are all now approved by HSA.
With the HSA approval for the 1Bio™AI-Acute toolbox, Respiree is now setting its sights on expanding the 1Bio™AI-Acute regulatory approvals across other APAC and ANZ regions, as well as in the United States, in the coming months.
HSA's approval of the 1Bio™AI-Acute toolbox follows the validation study that was recently peer-reviewed and published in the Mayo Clinic Proceedings.
About Respiree
Respiree™ is an AI/ML health tech company building clinically-validated AI for managing disease progression. Respiree™ products are CE marked and has received regulatory clearances from the Therapeutic Goods Administration and the United States Food and Drug Administration (FDA).
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION
SINGAPORE, April 2, 2026 /PRNewswire/ -- For decades, beer ads have belonged to the big guys, million-dollar productions, glossy beaches and celebrity cameos that cost more than a craft brewery makes in a year. For independent brewers like Brewlander, it was never a fair fight. Until now.
With the rise of text-to-video AI like Sora and Qwen 2.5, the rules have changed. Today, anyone with a keyboard can make an epic film without spending a cent. So Brewlander decided to do just that.
To show how Brewlander is the beer that invests in the beer, the brand didn't film commercials, it printed them. Posters, billboards, magazines, all featuring detailed AI prompts that anyone could type in to instantly generate over-the-top beer ads. The kind of ads independent brewers were never supposed to afford.
Examples included:
"Surfers ride black sea horses through an underwater world of neon coral reefs, past glowing jellyfish, raising their ice-cold Brewlanders."
"A colossal Brewlander bottle floats in a galaxy of bubble-planets and star-balls."
To make it even more rewarding, fans who generated their own Brewlander ads received exclusive discounts on the beer.
At the end of the day, the message was a brilliant move: Brewlander doesn't invest in million-dollar commercials, it invests in what matters: the beer itself.
About Brewlander
Brewlander was born out of John's passion for homebrewing (and his online moniker on brewing forums), and we've kept that homebrew tradition of having fun and pushing the envelope well alive.
Back in 2016, John and a few friends came up with a wild idea: to make his award-winning brews available to the wider public. Taking a leap of faith, he gave up his day job and plunged headfirst into the project with the mission to challenge the status quo of Asia's beer scene, while putting Singaporean brews on the world beer map.
Brewlander splashed onto Singapore's craft beer scene on 14 March 2017, launching to glowing response from the local beer community and the media as Singapore's first gypsy brewer.
About BLKJ Havas
BLKJ Havas is a creative company that engineers marketing moments for brands in culture, entertainment and media. It prides itself as the un-advertising agency - because people hate advertising, and we love people.
Now more than 8 years in business, the agency is amongst the most awarded and successful in the region. It is currently ranked the #1 Agency in Singapore, #8 in Asia by Campaign Brief THE WORK 2024. It is Spikes Asia 2024's Singapore Agency of the Year, and Top 10 APAC Agency of the Year.
Its strong regional and Singapore client roster includes Reckitt, JLL, JBL Harman, Great Eastern, Land Transport Authority of Singapore, Republic of Singapore Air Force, Singapore Tourism Board, Ministry of Education Singapore, IMDA and more.
For more, check out: blkjhavas.agency
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
THIS BEER BRAND DIDN'T FILM COMMERCIALS, IT PRINTED THEM
